{
    "id": "dbpedia_1686_2",
    "rank": 11,
    "data": {
        "url": "https://www.dana-farber.org/find-a-doctor/nikhil-c-munshi",
        "read_more_link": "",
        "language": "en",
        "title": "Nikhil C. Munshi, MD - Dana-Farber Cancer Institute",
        "top_image": "https://www.dana-farber.org/sites/default/files/favicon.ico",
        "meta_img": "https://www.dana-farber.org/sites/default/files/favicon.ico",
        "images": [
            "https://dfci.widen.net/content/110ca04f-81c4-49f9-8e22-28a6ce5b3d0d/web/DFCI%20Logo%20Lens%20Color-rgb.svg",
            "https://dfci.widen.net/content/ri9n147djk/web/nurse-practitioner-and-patient556x381.jpg?crop=yes&k=c&w=600&h=368&itok=d4Yi5_AR",
            "https://dfci.widen.net/content/htfmtrxnyd/web/healthy-raw-vegetables556x381.jpg?crop=yes&k=c&w=600&h=368&itok=IcqGg6fP",
            "https://dfci.widen.net/content/oxtykuypie/web/Maria-Luisa-Guerrera-Bing%20Center-Waldenstr%C3%B6ms-Macroglobulinemia?crop=yes&k=c&w=600&h=368&itok=OQoc7eAo",
            "https://dfci.widen.net/content/f8qik7fbpb/web/cpop-team?crop=yes&k=c&w=600&h=368&itok=POlIPQUu",
            "https://dfci.widen.net/content/ty10dsbqhz/web/Jimmy-Fund-Telethon?crop=yes&k=c&w=600&h=368&itok=8Cd5sQ2d",
            "https://dfci.widen.net/content/megjz0gzpk/web/kimmie-ng-and-patient556x381.jpg?crop=yes&k=c&w=600&h=368&itok=patrnNAo",
            "https://dfci.widen.net/content/110ca04f-81c4-49f9-8e22-28a6ce5b3d0d/web/DFCI%20Logo%20Lens%20Color-rgb.svg",
            "https://www.dana-farber.org/sites/default/files/providers/29587.jpg",
            "https://www.dana-farber.org/sites/default/files/providers/top-doctor-award.png",
            "https://www.dana-farber.org/sites/default/files/styles/location_listing_image_desktop/public/providers/location_avtar.png?itok=ftkJEpXC",
            "https://www.dana-farber.org/sites/default/files/styles/location_listing_image_desktop/public/providers/location_avtar.png?itok=ftkJEpXC",
            "https://dfci.widen.net/content/ptd61fuomf/web/yawkey-building-new-logo556x381.jpg?crop=yes&k=c&w=392&h=275&itok=nH-v10ZI 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/yawkey-building-new-logo%285%29.jpg?itok=EJBXkf8u 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/Riney%2520photo.jpg?itok=ogrXVDcE 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/SOG_8580_20%282%29.jpg?itok=ExX_EA1M 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/Nikhil%2520Munshi_DFCI%283%29.jpg?itok=pjTqLPe5 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/SOG_5354_20%283%29.jpg?itok=dv64cmaE 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/Nikhil%2520Munshi_DFCI%282%29.jpg?itok=Ua-wVs7i 1x",
            "https://dfci.widen.net/content/abby113pky/web/Nikhil%20Munshi_DFCI(1)376x566.jpg?crop=yes&k=c&w=392&h=275&itok=8C3s0UT5 1x",
            "https://www.dana-farber.org/sites/default/files/styles/card_392x275_/public/uploadedimages/expressreleases/Dana%2520Farber%2520Exterior.jpg?itok=RaovbFev 1x",
            "https://dfci.widen.net/content/b77baa3d-5752-4cb4-b5fa-a7a932a6d0bf/web/branded-main-nav-logo630x155.png",
            "https://dfci.widen.net/content/74dbf2d2-1d7d-42a1-ba0a-403d6a65b0e1/web/magnet_recognition_logo_pms_3278.png",
            "https://dfci.widen.net/content/336fa306-616e-4ea9-8e39-7d6fdcd303eb/web/compcancercenter_v_rgb_color_badge.png",
            "https://dfci.widen.net/content/f4982a29-b2d1-4858-acdc-41c69a51adcd/web/us-news-adult-badge-2024-2025-143x140.png",
            "https://dfci.widen.net/content/fd625301-4c6c-457c-833e-ecb73ab1c1cb/web/us-news-pediatric-badge-2023-2024.png",
            "https://dfci.widen.net/content/564abc40-3275-4121-b409-143db5df0262/web/nccn_logo_stacked-01.png",
            "https://dfci.widen.net/content/ec46f092-0d9a-4bab-8c94-9d4f247e7095/web/hms-affiliate-logo-250.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2023-11-15T12:00:00+00:00",
        "summary": "",
        "meta_description": "Nikhil C. Munshi, MD - Medical Oncology",
        "meta_lang": "en",
        "meta_favicon": "/sites/default/files/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://www.dana-farber.org/find-a-doctor/nikhil-c-munshi",
        "text": "Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024 Jun 11; 8(11):2952-2959. View in: Pubmed\n\nProposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma. Blood Adv. 2024 May 22. View in: Pubmed\n\nBone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes. Nat Commun. 2024 May 16; 15(1):4139. View in: Pubmed\n\nEditor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2024 May 15; 30(10):2288. View in: Pubmed\n\nCorrection to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2024 May; 38(5):1189-1190. View in: Pubmed\n\nRound Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discov. 2024 May 01; 5(3):146-152. View in: Pubmed\n\nAcute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179. View in: Pubmed\n\nIsatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial. Lancet Haematol. 2024 Jun; 11(6):e415-e424. View in: Pubmed\n\nAuthor Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2024 Apr; 30(4):1214. View in: Pubmed\n\nAuthor Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2024 Apr; 30(4):1210. View in: Pubmed\n\nLoss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024 Mar 29. View in: Pubmed\n\nRetraction: Nuclear Factor-?B p65 Mediates Tumor Necrosis Factor a-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein. Cancer Res. 2024 Mar 15; 84(6):939. View in: Pubmed\n\nRetraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Res. 2024 Mar 15; 84(6):936. View in: Pubmed\n\nRetraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of ß1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling. Cancer Res. 2024 Mar 15; 84(6):938. View in: Pubmed\n\nRetraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line. Cancer Res. 2024 Mar 15; 84(6):940. View in: Pubmed\n\nRetraction: Effects of Oligonucleotide N3'?P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells. Cancer Res. 2024 Mar 15; 84(6):937. View in: Pubmed\n\nABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma. Blood. 2024 Mar 14; 143(11):996-1005. View in: Pubmed\n\nRedefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier. Leukemia. 2024 May; 38(5):1172-1177. View in: Pubmed\n\nDifferentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8aß+ T cells targeting multiple myeloma. Blood. 2024 Mar 07; 143(10):895-911. View in: Pubmed\n\nEditor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment. Clin Cancer Res. 2024 Feb 16; 30(4):922. View in: Pubmed\n\nEpigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma. Nat Commun. 2024 Feb 14; 15(1):1367. View in: Pubmed\n\nRole of minimal residual disease assessment in multiple myeloma. Haematologica. 2024 Feb 08. View in: Pubmed\n\nImpact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma. Blood Adv. 2024 01 09; 8(1):219-223. View in: Pubmed\n\nCellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies. JCO Precis Oncol. 2024 Jan; 8:e2300349. View in: Pubmed\n\nDIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification. Haematologica. 2024 Jan 01; 109(1):231-244. View in: Pubmed\n\nImmunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival. Front Oncol. 2023; 13:1271807. View in: Pubmed\n\nRandomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796. View in: Pubmed\n\nMonoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023 11 14; 7(21):6599-6603. View in: Pubmed\n\nEven after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders. Blood Adv. 2023 11 14; 7(21):6767-6770. View in: Pubmed\n\nClinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica. 2023 11 01; 108(11):2894-2912. View in: Pubmed\n\nMore intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284. View in: Pubmed\n\nRespiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023 09 26; 7(18):5485-5495. View in: Pubmed\n\nTime-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. Blood Cancer Discov. 2023 09 01; 4(5):365-373. View in: Pubmed\n\nIdecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023 09; 29(9):2286-2294. View in: Pubmed\n\nSingle-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023 07 27; 142(4):313-324. View in: Pubmed\n\nManagement of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023 07; 24(7):e293-e311. View in: Pubmed\n\nCDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023 06 08; 141(23):2841-2852. View in: Pubmed\n\nUbiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023 05 25; 141(21):2599-2614. View in: Pubmed\n\nElevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma. Gastroenterology. 2023 08; 165(2):357-373. View in: Pubmed\n\nHigh-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 04 06; 141(14):1724-1736. View in: Pubmed\n\nAnalysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023 06; 129:107074. View in: Pubmed\n\nThe location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 2023 03 30; 141(13):1574-1583. View in: Pubmed\n\nReport of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials. Semin Hematol. 2023 03; 60(2):118-124. View in: Pubmed\n\nSpatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023 03 14; 7(5):718-733. View in: Pubmed\n\nPeripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 2023 02 28; 7(4):482-490. View in: Pubmed\n\nWhole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood. 2023 02 09; 141(6):620-633. View in: Pubmed\n\nA MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023 01 26; 141(4):391-405. View in: Pubmed\n\nGenetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers (Basel). 2023 Jan 15; 15(2). View in: Pubmed\n\nImproving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19. View in: Pubmed\n\nValidation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiol Drug Saf. 2023 05; 32(5):558-566. View in: Pubmed\n\nIn-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors. Blood Cancer J. 2022 12 20; 12(12):171. View in: Pubmed\n\nAuthor Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 Dec 13; 13(1):7725. View in: Pubmed\n\nRAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. Cancers (Basel). 2022 Nov 20; 14(22). View in: Pubmed\n\nRecent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study. Proc Natl Acad Sci U S A. 2022 11 16; 119(46):e2213783119. View in: Pubmed\n\nIn Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations. J Clin Oncol. 2023 03 20; 41(9):1695-1702. View in: Pubmed\n\nQuality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022 09 13; 6(17):4967-4974. View in: Pubmed\n\nTherapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia. Exp Hematol Oncol. 2022 Sep 12; 11(1):54. View in: Pubmed\n\nIncreased COVID-19 breakthrough infection risk in patients with plasma cell disorders. Blood. 2022 08 18; 140(7):782-785. View in: Pubmed\n\n?-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022 08 16; 12(8):118. View in: Pubmed\n\nComprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica. 2022 08 01; 107(8):1891-1901. View in: Pubmed\n\nPatient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. Leuk Res. 2022 09; 120:106921. View in: Pubmed\n\nA new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338. View in: Pubmed\n\nTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147. View in: Pubmed\n\nCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274. View in: Pubmed\n\nApoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. Haematologica. 2022 06 01; 107(6):1410-1426. View in: Pubmed\n\nIdentification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. J Clin Oncol. 2022 09 20; 40(27):3132-3150. View in: Pubmed\n\nHealth-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022 02 22; 6(4):1309-1318. View in: Pubmed\n\nQuality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022 05 15; 128(10):1996-2004. View in: Pubmed\n\nDeciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun. 2022 02 10; 13(1):807. View in: Pubmed\n\nPrognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 02 10; 139(6):835-844. View in: Pubmed\n\nConsensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161. View in: Pubmed\n\nAssociation of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. JAMA Oncol. 2022 02 01; 8(2):281-286. View in: Pubmed\n\nClonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv. 2022 01 25; 6(2):441-451. View in: Pubmed\n\nCell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 04; 36(4):1078-1087. View in: Pubmed\n\nFunctional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 01 10; 13(1):151. View in: Pubmed\n\nCD44 v5 domain inhibition represses the polarization of Th2 cells by interfering with the IL-4/IL-4R signaling pathway. Immunol Cell Biol. 2022 01; 100(1):21-32. View in: Pubmed\n\nCCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways. Oncotarget. 2021 Nov 23; 12(24):2323-2337. View in: Pubmed\n\nIgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021 11 18; 138(20):1980-1985. View in: Pubmed\n\nThe HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979. View in: Pubmed\n\nDysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. Blood Cancer J. 2021 10 08; 11(10):166. View in: Pubmed\n\nMinimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 01; 27(19):5195-5212. View in: Pubmed\n\nBCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin Cancer Res. 2021 10 01; 27(19):5376-5388. View in: Pubmed\n\nLack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021 09 28; 5(18):3511-3514. View in: Pubmed\n\nIndatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021 Nov; 8(11):e794-e807. View in: Pubmed\n\nClonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986. View in: Pubmed\n\nThe DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability. Genome Med. 2021 08 09; 13(1):127. View in: Pubmed\n\nDefining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093. View in: Pubmed\n\nTargeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022 01; 36(1):138-154. View in: Pubmed\n\nPathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma. Cancers (Basel). 2021 Jun 25; 13(13). View in: Pubmed\n\nCiltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324. View in: Pubmed\n\nDetection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer J. 2021 06 21; 11(6):117. View in: Pubmed\n\nCovid-19 vaccination in patients with multiple myeloma: Focus on immune response. Am J Hematol. 2021 08 01; 96(8):896-900. View in: Pubmed\n\nContemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers (Basel). 2021 Jun 18; 13(12). View in: Pubmed\n\nIdecabtagene Vicleucel in Relapsed Myeloma. Reply. N Engl J Med. 2021 06 17; 384(24):2357-2358. View in: Pubmed\n\nERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 06; 7(23). View in: Pubmed\n\nPrevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2021 06 01; 113(6):691-698. View in: Pubmed\n\nIntegrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. Commun Biol. 2021 05 24; 4(1):617. View in: Pubmed\n\nBortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 09; 2(5):468-483. View in: Pubmed\n\nLysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discov. 2021 07; 2(4):370-387. View in: Pubmed\n\nmiR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919. View in: Pubmed\n\nTreatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118. View in: Pubmed\n\nIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716. View in: Pubmed\n\nBiallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868. View in: Pubmed\n\nTreatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e119-e130. View in: Pubmed\n\nIdentification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. 2021 01 13; 11(1):13. View in: Pubmed\n\nRisk factors in multiple myeloma: is it time for a revision? Blood. 2021 01 07; 137(1):16-19. View in: Pubmed\n\nCRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. Methods Mol Biol. 2021; 2348:189-204. View in: Pubmed\n\nIn Vitro Silencing of lncRNAs Using LNA GapmeRs. Methods Mol Biol. 2021; 2348:157-166. View in: Pubmed\n\nClinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040. View in: Pubmed\n\nA large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999. View in: Pubmed\n\nInternational evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 12 08; 4(23):6039-6050. View in: Pubmed\n\nCisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723. View in: Pubmed\n\nClinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06. View in: Pubmed\n\nVIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110. View in: Pubmed\n\nDon't Compromise Myeloma Care Due to COVID-19 Pandemic! Blood Cancer Discov. 2020 11; 1(3):218-220. View in: Pubmed\n\nRevealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020 11; 1(3):258-273. View in: Pubmed\n\nThe immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 09 08; 4(17):4195-4207. View in: Pubmed\n\nYWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479. View in: Pubmed\n\nGenome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118. View in: Pubmed\n\nPreclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2021 03; 35(3):752-763. View in: Pubmed\n\nThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020 07; 8(2). View in: Pubmed\n\nCorrection: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971. View in: Pubmed\n\nClonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996. View in: Pubmed\n\nGenomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389. View in: Pubmed\n\nVitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020 04 28; 4(8):1643-1646. View in: Pubmed\n\nTiming the initiation of multiple myeloma. Nat Commun. 2020 04 21; 11(1):1917. View in: Pubmed\n\nc-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020 Jul; 105(1):35-46. View in: Pubmed\n\nTargeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044. View in: Pubmed\n\nMoving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol. 2020 03 01; 6(3):425-432. View in: Pubmed\n\nA novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 08; 34(8):2150-2162. View in: Pubmed\n\nMultiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 07; 34(7):1866-1874. View in: Pubmed\n\nThe Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers (Basel). 2020 Jan 30; 12(2). View in: Pubmed\n\nRAD51 Inhibitor Reverses Etoposide-Induced Genomic Toxicity and Instability in Esophageal Adenocarcinoma Cells. Arch Clin Toxicol (Middlet). 2020; 2(1):3-9. View in: Pubmed\n\nAmplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. Blood Adv. 2019 12 10; 3(23):3968-3972. View in: Pubmed\n\nHuman MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019 11 12; 3(21):3360-3374. View in: Pubmed\n\nMonitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020 02; 34(2):578-588. View in: Pubmed\n\nPhase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253. View in: Pubmed\n\nSummary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020 01; 26(1):e7-e15. View in: Pubmed\n\nMonoclonal Gammopathy May Be of Unpredictable Significance. JAMA Oncol. 2019 Sep 01; 5(9):1302-1303. View in: Pubmed\n\nGenomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835. View in: Pubmed\n\nBCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223. View in: Pubmed\n\nAuthor Correction: A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019 Jul 25; 10(1):3431. View in: Pubmed\n\nA practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019 07 05; 10(1):2969. View in: Pubmed\n\nThe effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020 01; 34(1):167-179. View in: Pubmed\n\nPembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. Br J Haematol. 2019 09; 186(5):e117-e121. View in: Pubmed\n\nAnti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737. View in: Pubmed\n\nPatterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170. View in: Pubmed\n\nWith equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019 06 13; 133(24):2615-2618. View in: Pubmed\n\nDeciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39. View in: Pubmed\n\nSelective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226. View in: Pubmed\n\nIndatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):372-380. View in: Pubmed\n\nImmunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):332-344. View in: Pubmed\n\nNovel Agents in Multiple Myeloma. Cancer J. 2019 Jan/Feb; 25(1):45-53. View in: Pubmed\n\nIntroduction by the Guest Editor: At a Crossroad to Cure: From Molecule to Management Strategies in Multiple Myeloma. Cancer J. 2019 Jan/Feb; 25(1):1. View in: Pubmed\n\nNon-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6. View in: Pubmed\n\nVariable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). Blood. 2018 12 27; 132(26):2778-2780. View in: Pubmed\n\nInsights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946. View in: Pubmed\n\nPhase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112. View in: Pubmed\n\nSummary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2019 03; 25(3):e89-e97. View in: Pubmed\n\nThe roles of homologous recombination and the immune system in the genomic evolution of cancer. J Transl Sci. 2019 Apr; 5(2). View in: Pubmed\n\nRole of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance. Blood Cancer J. 2018 09 25; 8(10):92. View in: Pubmed\n\nA multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Adv. 2018 09 25; 2(18):2400-2411. View in: Pubmed\n\nMinimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464. View in: Pubmed\n\nDual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377. View in: Pubmed\n\nInternational, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124. View in: Pubmed\n\nAPRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438. View in: Pubmed\n\nGenomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018 08 22; 9(1):3363. View in: Pubmed\n\nThe evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574. View in: Pubmed\n\nTherapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood. 2018 09 06; 132(10):1050-1063. View in: Pubmed\n\nA high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170. View in: Pubmed\n\nMultiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018 12; 32(12):2636-2647. View in: Pubmed\n\nIdentification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597. View in: Pubmed\n\nAnalysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616. View in: Pubmed\n\nA phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230. View in: Pubmed\n\nWidespread intronic polyadenylation diversifies immune cell transcriptomes. Nat Commun. 2018 04 30; 9(1):1716. View in: Pubmed\n\nAntigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight. 2018 04 19; 3(8). View in: Pubmed\n\nLong intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635. View in: Pubmed\n\nGenomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841. View in: Pubmed\n\nTolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):422-430. View in: Pubmed\n\nHistone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947. View in: Pubmed\n\nDrugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018 09; 32(9):1948-1957. View in: Pubmed\n\nCastleman Disease. Hematol Oncol Clin North Am. 2018 02; 32(1):xiii-xiv. View in: Pubmed\n\nDiagnosis of Castleman Disease. Hematol Oncol Clin North Am. 2018 02; 32(1):53-64. View in: Pubmed\n\nBMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biol Blood Marrow Transplant. 2018 04; 24(4):641-648. View in: Pubmed\n\nAnalysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2017 Dec 06. View in: Pubmed\n\nBiological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia. 2018 04; 32(4):1044-1048. View in: Pubmed\n\nExpressed fusion gene landscape and its impact in multiple myeloma. Nat Commun. 2017 12 01; 8(1):1893. View in: Pubmed\n\nMiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia. 2018 04; 32(4):1003-1015. View in: Pubmed\n\nProtein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018 04; 32(4):996-1002. View in: Pubmed\n\nDetermining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Nat Commun. 2017 11 20; 8(1):1613. View in: Pubmed\n\nIdentification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia. 2018 03; 32(3):752-764. View in: Pubmed\n\n14-3-3? binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia. 2018 03; 32(3):744-751. View in: Pubmed\n\nLogic programming reveals alteration of key transcription factors in multiple myeloma. Sci Rep. 2017 08 23; 7(1):9257. View in: Pubmed\n\nMyeloma Minimal Residual Disease and Surrogacy-Reply. JAMA Oncol. 2017 08 01; 3(8):1136-1137. View in: Pubmed\n\nProspective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918. View in: Pubmed\n\nILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6. View in: Pubmed\n\nNucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2018 01; 32(1):111-119. View in: Pubmed\n\nBlockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017 10 05; 36(40):5631-5638. View in: Pubmed\n\nNext-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. Cancer. 2017 Oct 01; 123(19):3701-3708. View in: Pubmed\n\nRibonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237. View in: Pubmed\n\nThe Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 01; 23(15):3980-3993. View in: Pubmed\n\nLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320. View in: Pubmed\n\nThe Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224. View in: Pubmed\n\nBlockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289. View in: Pubmed\n\nTargeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. 2017 Aug 01; 23(15):4290-4300. View in: Pubmed\n\nImpact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. J Gastroenterol Hepatol Res. 2017; 6(1):2286-2295. View in: Pubmed\n\nGenomics of Multiple Myeloma. J Clin Oncol. 2017 Mar 20; 35(9):963-967. View in: Pubmed\n\nFunctional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245. View in: Pubmed\n\np53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319. View in: Pubmed\n\nAssociation of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35. View in: Pubmed\n\nThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. View in: Pubmed\n\nDeficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis. Oncoimmunology. 2017; 6(1):e1261776. View in: Pubmed\n\nA novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341. View in: Pubmed\n\nGene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res. 2016 Nov 15; 22(22):5434-5442. View in: Pubmed\n\nA DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J. 2016 09 02; 6(9):e467. View in: Pubmed\n\nA Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. View in: Pubmed\n\nInternational Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346. View in: Pubmed\n\nDNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. Blood. 2016 09 01; 128(9):1214-25. View in: Pubmed\n\nOsteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016 09 22; 128(12):1590-603. View in: Pubmed\n\nReview of siltuximab in the treatment of multicentric Castleman's disease. Ther Adv Hematol. 2016 Dec; 7(6):360-366. View in: Pubmed\n\nDual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109. View in: Pubmed\n\nStromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology. 2016 Aug; 5(8):e1189052. View in: Pubmed\n\nA clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52. View in: Pubmed\n\nTherapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther. 2016 06; 15(6):1364-75. View in: Pubmed\n\nAPRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36. View in: Pubmed\n\nA Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clin Cancer Res. 2016 Sep 01; 22(17):4350-4355. View in: Pubmed\n\nTherapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016 Mar 28. View in: Pubmed\n\nCorrigendum to \"Genomic heterogeneity in multiple myeloma\" [Curr. Opin. Genet. Dev. 30 (2015) 56-65]. Curr Opin Genet Dev. 2016 04; 37:158. View in: Pubmed\n\nRegulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res. 2016 06; 31(6):1225-34. View in: Pubmed\n\nImpact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. Clin Cancer Res. 2016 Aug 15; 22(16):4039-44. View in: Pubmed\n\nmiR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016 Jan 15; 6:e380. View in: Pubmed\n\nCancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Res. 2016 Jan 15; 76(2):463-71. View in: Pubmed\n\nThe KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258. View in: Pubmed\n\nNext-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. Am Soc Clin Oncol Educ Book. 2016; 35:e442-8. View in: Pubmed\n\nRole of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13. View in: Pubmed\n\nGene signature combinations improve prognostic stratification of multiple myeloma patients. Leukemia. 2016 05; 30(5):1071-8. View in: Pubmed\n\nEvidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50. View in: Pubmed\n\nDeep Response in Multiple Myeloma: A Critical Review. Biomed Res Int. 2015; 2015:832049. View in: Pubmed\n\nBone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84. View in: Pubmed\n\nCombination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847. View in: Pubmed\n\nDeficiency of IL-17A, but not the prototypical Th17 transcription factor ROR?t, decreases murine spontaneous intestinal tumorigenesis. Cancer Immunol Immunother. 2016 Jan; 65(1):13-24. View in: Pubmed\n\nA 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016 Mar 01; 22(5):1222-33. View in: Pubmed\n\nAssociation of Agent Orange With Plasma Cell Disorder: Further Evidence. JAMA Oncol. 2015 Nov; 1(8):1035-6. View in: Pubmed\n\nSolitary Extramedullary Multiple Myeloma Presenting with Small Bowel Obstruction. J Emerg Med. 2016 Jan; 50(1):e25-7. View in: Pubmed\n\nSAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016 Feb; 30(2):399-408. View in: Pubmed\n\nTargeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia. 2016 Feb; 30(2):379-89. View in: Pubmed\n\nTargeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015 Oct 15; 75(20):4384-4397. View in: Pubmed\n\nAnalysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015 Oct 01; 21(19):4294-304. View in: Pubmed\n\nDevelopment of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50. View in: Pubmed\n\nThe Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80. View in: Pubmed\n\nA Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Sep 15; 21(18):4055-61. View in: Pubmed\n\nSelective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015 Nov; 29(11):2173-83. View in: Pubmed\n\nGenomic heterogeneity in multiple myeloma. Curr Opin Genet Dev. 2015 02; 30:56-65. View in: Pubmed\n\nLenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18. View in: Pubmed\n\nRational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015 May 15; 5:e312. View in: Pubmed\n\nLenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2). View in: Pubmed\n\nPathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015 May 14; 125(20):3049-58. View in: Pubmed\n\nPatient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient. 2015 Apr; 8(2):207-16. View in: Pubmed\n\nIncidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8. View in: Pubmed\n\nMultimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol. 2015 May; 88(1049):20140670. View in: Pubmed\n\nTargeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015 Jun; 29(6):1441-4. View in: Pubmed\n\nRole of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood. 2015 Mar 26; 125(13):2095-100. View in: Pubmed\n\nGenetics of multiple myeloma: another heterogeneity level? Blood. 2015 Mar 19; 125(12):1870-6. View in: Pubmed\n\nA Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43. View in: Pubmed\n\nHeteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914. View in: Pubmed\n\nEarly or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61. View in: Pubmed\n\nAnti-tumor activities of selective HSP90a/ß inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia. 2015 Feb; 29(2):510-4. View in: Pubmed\n\nOrigins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife. 2014 Oct 01; 3. View in: Pubmed\n\nImmunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):927-43. View in: Pubmed\n\nUse of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015 May; 56(5):1252-60. View in: Pubmed\n\nDifferential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7. View in: Pubmed\n\nPyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86. View in: Pubmed\n\nA Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014 Nov; 167(3):366-75. View in: Pubmed\n\nSiltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug; 15(9):966-74. View in: Pubmed\n\nTreatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11. View in: Pubmed\n\nCSNK1a1 mediates malignant plasma cell survival. Leukemia. 2015 Feb; 29(2):474-82. View in: Pubmed\n\nBiomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61. View in: Pubmed\n\nCCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. PLoS One. 2014; 9(5):e97566. View in: Pubmed\n\nA multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015 Jan; 29(1):218-29. View in: Pubmed\n\nManagement of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma. J Clin Oncol. 2016 Jan 10; 34(2):e1-5. View in: Pubmed\n\nOutcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9. View in: Pubmed\n\nGene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014 Nov; 28(11):2229-34. View in: Pubmed\n\nProcessed pseudogenes acquired somatically during cancer development. Nat Commun. 2014 Apr 09; 5:3644. View in: Pubmed\n\nMRI features of extramedullary myeloma. AJR Am J Roentgenol. 2014 Apr; 202(4):803-10. View in: Pubmed\n\nMYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81. View in: Pubmed\n\nmiR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13. View in: Pubmed\n\nNovel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38. View in: Pubmed\n\nA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9. View in: Pubmed\n\nImmunotherapy for multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):91-6. View in: Pubmed\n\nReply to M. Roschewski et al. J Clin Oncol. 2014 Feb 10; 32(5):478. View in: Pubmed\n\nHeterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997. View in: Pubmed\n\nLenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014 Jan 17; 343(6168):301-5. View in: Pubmed\n\nA novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J. 2013 Nov 01; 3:e156. View in: Pubmed\n\nThe shaping and functional consequences of the dosage effect landscape in multiple myeloma. BMC Genomics. 2013 Oct 02; 14:672. View in: Pubmed\n\nBiology of telomeres: importance in etiology of esophageal cancer and as therapeutic target. Transl Res. 2013 Dec; 162(6):364-70. View in: Pubmed\n\nIndividualized therapy in multiple myeloma: are we there? Semin Oncol. 2013 Oct; 40(5):567-76. View in: Pubmed\n\nPhase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904. View in: Pubmed\n\nIdentification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51. View in: Pubmed\n\nIMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb; 28(2):269-77. View in: Pubmed\n\nSignatures of mutational processes in human cancer. Nature. 2013 Aug 22; 500(7463):415-21. View in: Pubmed\n\nTranscription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia. 2014 Apr; 28(4):894-903. View in: Pubmed\n\nHistone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014 Mar; 28(3):680-9. View in: Pubmed\n\nIntracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55. View in: Pubmed\n\nSmall-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec; 27(12):2366-75. View in: Pubmed\n\nMinimal residual disease in multiple myeloma. J Clin Oncol. 2013 Jul 10; 31(20):2523-6. View in: Pubmed\n\nInternational Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013 Jun 20; 31(18):2347-57. View in: Pubmed\n\nVaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8. View in: Pubmed\n\nChallenges in multiple myeloma diagnosis and treatment. Leuk Suppl. 2013 May; 2(Suppl 1):S3-9. View in: Pubmed\n\nTargeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene. 2014 Mar 20; 33(12):1495-505. View in: Pubmed\n\nCRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan; 28(1):155-65. View in: Pubmed\n\nIn vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31. View in: Pubmed\n\nProceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3. View in: Pubmed\n\nNew strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44. View in: Pubmed\n\nClassify hyperdiploidy status of multiple myeloma patients using gene expression profiles. PLoS One. 2013; 8(3):e58809. View in: Pubmed\n\nTargeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 15; 19(8):2096-106. View in: Pubmed\n\ncanEvolve: a web portal for integrative oncogenomics. PLoS One. 2013; 8(2):e56228. View in: Pubmed\n\nIn vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013 Apr; 53(2):487-96. View in: Pubmed\n\nMYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8. View in: Pubmed\n\nTumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87. View in: Pubmed\n\nHeat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71. View in: Pubmed\n\nPhase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7. View in: Pubmed\n\nEndothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8. View in: Pubmed\n\nmiR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012 Nov 29; 3:e436. View in: Pubmed\n\nResponse assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6. View in: Pubmed\n\nSynthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012 Nov 15; 18(22):6260-70. View in: Pubmed\n\nA small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58. View in: Pubmed\n\nTargeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29. View in: Pubmed\n\nTargeted disruption of the BCL9/ß-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 2012 Aug 22; 4(148):148ra117. View in: Pubmed\n\nMinor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013 Feb; 27(2):473-81. View in: Pubmed\n\nPathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61. View in: Pubmed\n\nCanonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13. View in: Pubmed\n\nMyeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60. View in: Pubmed\n\nBruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87. View in: Pubmed\n\nA novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012 Jun; 157(6):687-701. View in: Pubmed\n\nBlockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81. View in: Pubmed\n\nThe potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9. View in: Pubmed\n\nTargeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. Cancer Genomics Proteomics. 2012 Mar-Apr; 9(2):55-66. View in: Pubmed\n\nLatest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43. View in: Pubmed\n\nManagement of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8. View in: Pubmed\n\nCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8. View in: Pubmed\n\nNovel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50. View in: Pubmed\n\nPotent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 01; 119(9):2074-82. View in: Pubmed\n\nManagement of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608. View in: Pubmed\n\nThe Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7. View in: Pubmed\n\nPerifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9. View in: Pubmed\n\nManagement of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16. View in: Pubmed\n\nSomatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 Oct 13; 365(15):1384-95. View in: Pubmed\n\nNovel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61. View in: Pubmed\n\nSignificant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9. View in: Pubmed\n\nManaging multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62. View in: Pubmed\n\nVorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leuk Lymphoma. 2011 Sep; 52(9):1777-86. View in: Pubmed\n\nIdentification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia. 2011 Oct; 25(10):1610-9. View in: Pubmed\n\nMGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596. View in: Pubmed\n\nChromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011 Jul 21; 118(3):675-8. View in: Pubmed\n\nA phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8. View in: Pubmed\n\nEfficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. J Clin Oncol. 2011 May 20; 29(15_suppl):8074. View in: Pubmed\n\nComplete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11(3):298-302. View in: Pubmed\n\nAntimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71. View in: Pubmed\n\nGenomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene. 2011 Aug 18; 30(33):3585-98. View in: Pubmed\n\nGenomics in multiple myeloma. Clin Cancer Res. 2011 Mar 15; 17(6):1234-42. View in: Pubmed\n\nThe dChip survival analysis module for microarray data. BMC Bioinformatics. 2011 Mar 09; 12:72. View in: Pubmed\n\nWeekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72. View in: Pubmed\n\nConsensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700. View in: Pubmed\n\nConsensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5. View in: Pubmed\n\nConsensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5. View in: Pubmed\n\nHistone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):152-6. View in: Pubmed\n\nA unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia. 2011 Apr; 25(4):707-11. View in: Pubmed\n\nMolecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32. View in: Pubmed\n\nAnticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol. 2010 Dec 01; 3(6):389-99. View in: Pubmed\n\nHDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia. 2011 Jan; 25(1):161-8. View in: Pubmed\n\nVaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402. View in: Pubmed\n\nMicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20. View in: Pubmed\n\nImmunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37. View in: Pubmed\n\nLenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45. View in: Pubmed\n\nPI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8. View in: Pubmed\n\nThe treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009. View in: Pubmed\n\nMechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S7-13. View in: Pubmed\n\nElevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92. View in: Pubmed\n\nLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86. View in: Pubmed\n\nA novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13. View in: Pubmed\n\nDual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010 Apr; 9(4):963-75. View in: Pubmed\n\nTumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9. View in: Pubmed\n\nA proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5. View in: Pubmed\n\nBlockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49. View in: Pubmed\n\nTailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9. View in: Pubmed\n\nActivin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9. View in: Pubmed\n\nA phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 May; 95(5):845-8. View in: Pubmed\n\nConflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. View in: Pubmed\n\nAT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22; 29(16):2325-36. View in: Pubmed\n\nThe sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34. View in: Pubmed\n\nInteractions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60. View in: Pubmed\n\nA high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52. View in: Pubmed\n\nFunctional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23. View in: Pubmed\n\nNovel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60. View in: Pubmed\n\nMulticenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9. View in: Pubmed\n\nIn vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6. View in: Pubmed\n\nThe use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32. View in: Pubmed\n\nBortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17. View in: Pubmed\n\nHigh-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39. View in: Pubmed\n\nPrognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009 Sep 20; 27(27):4585-90. View in: Pubmed\n\nIdentification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84. View in: Pubmed\n\nAntimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42. View in: Pubmed\n\nMobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35. View in: Pubmed\n\nInternational myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Oct; 23(10):1904-12. View in: Pubmed\n\nSingle-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25. View in: Pubmed\n\nThe monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37. View in: Pubmed\n\nUse of alternate splicing to identify subgroups in uniformly treated newly-diagnosed myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):8602. View in: Pubmed\n\nClinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol. 2009 May 20; 27(15_suppl):8539. View in: Pubmed\n\nTNF-a, retinoid acid and STAT4 pathways are differentially regulated by the HDAC inhibitors, SAHA, TSA and Sirtinol in Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009 May 20; 27(15_suppl):e14582. View in: Pubmed\n\nBortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52. View in: Pubmed\n\nAnti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9. View in: Pubmed\n\nEmerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75. View in: Pubmed\n\nBiologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36. View in: Pubmed\n\nSinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601. View in: Pubmed\n\nCS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18. View in: Pubmed\n\nCXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51. View in: Pubmed\n\nPreclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009 May; 23(5):961-70. View in: Pubmed\n\nLenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60. View in: Pubmed\n\nDysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 2009 Mar 05; 113(10):2290-7. View in: Pubmed\n\nTargeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21. View in: Pubmed\n\nGeneration of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62. View in: Pubmed\n\nIn vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol. 2008 Nov; 143(4):520-31. View in: Pubmed\n\nThe research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4. View in: Pubmed\n\nTelomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008 Aug 01; 14(15):4971-80. View in: Pubmed\n\nLenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008 Oct; 22(10):1925-32. View in: Pubmed\n\nBortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72. View in: Pubmed\n\nAplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25. View in: Pubmed\n\nLenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5. View in: Pubmed\n\nUse of high-density SNP-array analysis to identify novel chromosomal abnormalities that predict survival in multiple myeloma. J Clin Oncol. 2008 May 20; 26(15_suppl):8522. View in: Pubmed\n\nPhase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008 May 20; 26(15_suppl):8545. View in: Pubmed\n\nTelomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008 Jul; 22(7):1410-8. View in: Pubmed\n\nCase records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. N Engl J Med. 2008 Apr 24; 358(17):1838-48. View in: Pubmed\n\nDichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol. 2008 Jun; 109(3):394-402. View in: Pubmed\n\nClinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95. View in: Pubmed\n\np38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May; 141(5):598-606. View in: Pubmed\n\nTargeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74. View in: Pubmed\n\nCD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9. View in: Pubmed\n\nMHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90. View in: Pubmed\n\nPlasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program. 2008; 297. View in: Pubmed\n\nInvestigative tools for diagnosis and management. Hematology Am Soc Hematol Educ Program. 2008; 298-305. View in: Pubmed\n\nImmune therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1217-30, x-xi. View in: Pubmed\n\nMonoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc. 2007 Dec; 82(12):1457-9. View in: Pubmed\n\nThe role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii. View in: Pubmed\n\nCombination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64. View in: Pubmed\n\nA practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. View in: Pubmed\n\nTargeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63. View in: Pubmed\n\nNeutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9. View in: Pubmed\n\nAnti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37. View in: Pubmed\n\nBiological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia. 2007 Dec; 21(12):2519-26. View in: Pubmed\n\nEstablishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75. View in: Pubmed\n\nInhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91. View in: Pubmed\n\nIntegration of novel agents into treatment of myeloma. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S215-21. View in: Pubmed\n\nAlkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46. View in: Pubmed\n\nMultiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68. View in: Pubmed\n\nPhenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7. View in: Pubmed\n\nNew drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89. View in: Pubmed\n\nDoes maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5. View in: Pubmed\n\nTargeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63. View in: Pubmed\n\nThe differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007 Apr; 11(4):349-60. View in: Pubmed\n\nHigh-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96. View in: Pubmed\n\nThe treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23. View in: Pubmed\n\nActivity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007 Mar 15; 109(6):2604-6. View in: Pubmed\n\nCan thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1. View in: Pubmed\n\nDifferential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood. 2007 Mar 01; 109(5):2001-7. View in: Pubmed\n\nTargeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7. View in: Pubmed\n\nTargeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77. View in: Pubmed\n\nA novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007 Apr 05; 26(16):2374-80. View in: Pubmed\n\nMLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94. View in: Pubmed\n\nLong-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64. View in: Pubmed\n\nDidox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol. 2006 Oct; 135(1):52-61. View in: Pubmed\n\nA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64. View in: Pubmed\n\nIn vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol. 2006 Jul; 134(1):37-44. View in: Pubmed\n\nRole of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82. View in: Pubmed\n\nGene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56. View in: Pubmed\n\nSpecific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10. View in: Pubmed\n\nNovel model to evaluate changes in gene expression profile of myeloma cells in vivo following interaction with human BM microenvironment. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7613. View in: Pubmed\n\nSingle-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7504. View in: Pubmed\n\nLenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7606. View in: Pubmed\n\nMast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006 Aug; 17(8):1275-82. View in: Pubmed\n\nThe role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73. View in: Pubmed\n\nAggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9. View in: Pubmed\n\nFQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704. View in: Pubmed\n\nPerifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62. View in: Pubmed\n\nImmunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20. View in: Pubmed\n\nAntimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100. View in: Pubmed\n\nDysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4. View in: Pubmed\n\nEmerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8. View in: Pubmed\n\nTumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant. 2005 Aug; 36(4):315-23. View in: Pubmed\n\nTelomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer. 2005 Jul 15; 4:24. View in: Pubmed\n\nHuman anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906. View in: Pubmed\n\nAntimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia. 2005 Jul; 19(7):1253-61. View in: Pubmed\n\nPhase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma. J Clin Oncol. 2005 Jun; 23(16_suppl):6581. View in: Pubmed\n\nMolecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9. View in: Pubmed\n\nSeliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 01; 106(3):1042-7. View in: Pubmed\n\nA clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005 Jul 15; 106(2):713-6. View in: Pubmed\n\nSDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12. View in: Pubmed\n\nAzaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6. View in: Pubmed\n\nGraft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50. View in: Pubmed\n\nProteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53. View in: Pubmed\n\np38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76. View in: Pubmed\n\nFocus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44. View in: Pubmed\n\nA global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 Sep 01; 10(17):5692-701. View in: Pubmed\n\nCombination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93. View in: Pubmed\n\nCytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 01; 104(12):3688-96. View in: Pubmed\n\nExcess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6555. View in: Pubmed\n\nIn vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004 Jul 01; 64(13):4629-36. View in: Pubmed\n\nMulticentric plasma cell variant of Castleman's disease with cutaneous involvement. J Cutan Pathol. 2004 Jul; 31(6):448-52. View in: Pubmed\n\nTargeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66. View in: Pubmed\n\nGrowth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 2004 May; 126(5):1337-46. View in: Pubmed\n\nBlockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene. 2004 Apr 29; 23(20):3597-602. View in: Pubmed\n\nMechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52. View in: Pubmed\n\nRecent advances in the management of multiple myeloma. Semin Hematol. 2004 Apr; 41(2 Suppl 4):21-6. View in: Pubmed\n\n2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27. Apoptosis. 2004 Mar; 9(2):149-55. View in: Pubmed\n\nPodocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004 Feb; 65(2):634-41. View in: Pubmed\n\nTelomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 Jan 15; 10(2):770-6. View in: Pubmed\n\nTranscriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5. View in: Pubmed\n\nThe bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66. View in: Pubmed\n\nAntitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36. View in: Pubmed\n\nProteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93. View in: Pubmed\n\nComplete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63. View in: Pubmed\n\nFluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96. View in: Pubmed\n\nEffects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 10 01; 63(19):6187-94. View in: Pubmed\n\nImmunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90. View in: Pubmed\n\nSuperoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300. View in: Pubmed\n\nInsulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 09 15; 63(18):5850-8. View in: Pubmed\n\nIdentification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806. View in: Pubmed\n\nTelomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003 Sep; 2(9):825-33. View in: Pubmed\n\nInsights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11. View in: Pubmed\n\nDTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9. View in: Pubmed\n\nHsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86. View in: Pubmed\n\nNVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22. View in: Pubmed\n\nViral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8. View in: Pubmed\n\nRole for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):282-5. View in: Pubmed\n\nTreatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6. View in: Pubmed\n\nJNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6. View in: Pubmed\n\nInfection--an underappreciated cause of bone pain in multiple myeloma. Br J Haematol. 2003 Mar; 120(6):1047-50. View in: Pubmed\n\nContinuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56. View in: Pubmed\n\nMolecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62. View in: Pubmed\n\nNuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21. View in: Pubmed\n\nAntisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res. 2003 Jan; 27(1):73-8. View in: Pubmed\n\nEssential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801. View in: Pubmed\n\nIdentification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14. View in: Pubmed\n\nCD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9. View in: Pubmed\n\nThe proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80. View in: Pubmed\n\nMolecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9. View in: Pubmed\n\nMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4. View in: Pubmed\n\n2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94. View in: Pubmed\n\nClinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 2002 Sep; 16(9):1835-7. View in: Pubmed\n\nProteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000. View in: Pubmed\n\nThe vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26. View in: Pubmed\n\nTelomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents. 2002 Sep; 2(5):567-75. View in: Pubmed\n\nActivation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83. View in: Pubmed\n\nArsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002 Aug; 1(10):851-60. View in: Pubmed\n\nNovel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1. View in: Pubmed\n\nbeta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20. View in: Pubmed\n\nCytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 07 01; 62(13):3876-82. View in: Pubmed\n\nApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30. View in: Pubmed\n\nBiologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86. View in: Pubmed\n\nAdeno-associated virus protects the retinoblastoma family of proteins from adenoviral-induced functional inactivation. Cancer Res. 2002 May 15; 62(10):2982-5. View in: Pubmed\n\nOptimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002 May; 117(2):297-305. View in: Pubmed\n\nThe biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002 May; 1(7):539-44. View in: Pubmed\n\nNF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47. View in: Pubmed\n\nIdentification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58. View in: Pubmed\n\nABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9. View in: Pubmed\n\nPredicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 Jan; 116(1):211-7. View in: Pubmed\n\nInteraction of adeno-associated virus Rep78 with SV40 T antigen: implications in Rep protein expression leading to the inhibition of SV40-mediated cell proliferation. Intervirology. 2002; 45(2):115-8. View in: Pubmed\n\nNephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 Dec 06; 345(23):1655-9. View in: Pubmed\n\nIncreased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001 Dec; 28(6):565-9. View in: Pubmed\n\nResults of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001 Sep; 114(4):822-9. View in: Pubmed\n\nAutologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001 Sep; 114(3):600-7. View in: Pubmed\n\nCoordination of a transcriptional switch by HMGI(Y) acetylation. Science. 2001 Aug 10; 293(5532):1133-6. View in: Pubmed\n\nExtended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001 Jul 15; 98(2):492-4. View in: Pubmed\n\nOverexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. Cancer Res. 2001 Jun 01; 61(11):4583-90. View in: Pubmed\n\nHigh response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001 May 01; 97(9):2574-9. View in: Pubmed\n\nDual level inhibition of E2F-1 activity by adeno-associated virus Rep78. J Biol Chem. 2001 Jun 29; 276(26):24315-22. View in: Pubmed\n\nCT-guided biopsy of focal lesions in patients with multiple myeloma may reveal new and more aggressive cytogenetic abnormalities. AJNR Am J Neuroradiol. 2001 Apr; 22(4):781-5. View in: Pubmed\n\nExpression of a free gamma heavy chain in serum following autologous stem cell transplantation for IgG kappa multiple myeloma. Bone Marrow Transplant. 2001 Mar; 27(6):663-6. View in: Pubmed\n\nDendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp Hematol. 2001 Jan; 29(1):85-92. View in: Pubmed\n\nExpression of AAV Rep proteins in SV40-transformed and untransformed cells: reciprocal interaction with host DNA synthesis. Intervirology. 2001; 44(5):298-305. View in: Pubmed\n\nArsenic trioxide: an emerging therapy for multiple myeloma. Oncologist. 2001; 6 Suppl 2:17-21. View in: Pubmed\n\nPreceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001 Jan; 112(1):242-7. View in: Pubmed\n\nMulticolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol. 2001 Jan; 112(1):167-74. View in: Pubmed\n\nTumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000 Oct 15; 96(8):2828-33. View in: Pubmed\n\nAn ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol. 2000 Oct; 20(20):7572-82. View in: Pubmed\n\nThe architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression. J Neurosci. 2000 Oct 01; 20(19):7317-24. View in: Pubmed\n\nResults of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000 Jun 15; 95(12):4008-10. View in: Pubmed\n\nMelphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant. 2000 Mar; 25(5):483-7. View in: Pubmed\n\nc-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells. J Immunol. 2000 Feb 01; 164(3):1169-74. View in: Pubmed\n\nA phase II trial of high dose epirubicin in patients with advanced breast carcinoma. Cancer. 2000 Jan 15; 88(2):375-80. View in: Pubmed\n\nAntitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18; 341(21):1565-71. View in: Pubmed\n\nKaposi's sarcoma-associated herpesvi"
    }
}